CORT

Korlym®(Relacorilant)

Hypercortisolism (Cushing Syndrome)

Phase 3

Exp Date

2022

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Relacorilant for Hypercortisolism (Cushing Syndrome) - Phase 3 

  • ClinicalTrial.gov (NCT03697109): A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE)


WHAT IS THE NEXT CATALYST EVENT?

  • Topline Data 

  • NDA Submission Based on Results 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • 2Q 2022 (Q3 2020 Financial Update)


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, one of the two receptors to which cortisol binds.  Relacorilant does not bind to the body's other hormone receptors, including the progesterone receptor.  Corcept is studying relacorilant as a potential treatment for a variety of serious disorders.

Updated by JM 

CORT, Hypercortisolism (Cushing Syndrome), Korlym®(Relacorilant), Corcept Therapeutics

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon